RxDoctor Payments Data

Michael Spencer, OD

Optometrist · Lehigh Acres, FLNPI 1912960022

Payments from drug & device makers

$2,388in general payments, 2019–2025

Across 64 payments — averaging $37.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$582
  • Alcon$353
  • Sight Sciences, Inc.$296
  • Biotissue Holdings Inc.$295
  • Kala Pharmaceuticals, Inc.$149
  • Astellas Pharma US Inc$135
  • plus $578 from 10 others

What the payments were for

  • Food & beverage$2,388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,388 in reported general payments places this provider in the 75th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$109,545
Medicare patients
360
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine101$72,318
XiidraLifitegrast23$23,836
LumiganBimatoprost35$17,564
RocklatanNetarsudil Mesylat/Latanoprost27$10,147
Cyclosporine17$6,720
SimbrinzaBrinzolamide/Brimonidine Tart17$4,916
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$3,347
Loteprednol Etabonate20$3,006
Prednisolone Acetate93$2,634
Latanoprost454$2,625
Brimonidine Tartrate318$2,322
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat94$920
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha77$877
Timolol Maleate130$822
Dorzolamide Hcl49$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$582$89,882136 claims
Bausch & Lomb Americas Inc.Xiidra$101$23,83623 claims
AlconSimbrinza$353$4,91617 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$26$3,00620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Lehigh Acres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →